北京华大基因的展位在第三届中国国际供应链促进博览会上。 IC供图 1月27日晚间，华大基因发布2025年度业绩预告。业绩预告显示，公司2025年营业收入预计为36亿元至 39亿元，归母净利润同比大幅减亏。华大基因表示，业绩变动主要受行业竞争加剧导致部分产品毛利率 下降幅度较大、客户回款周期延长带来的信用减值损失增加，以及对部分交付中心进行战略调整所计提 的资产减值等因素影响。 值得注意的是，华大基因通过精益运营有效控制费用，销售、管理及研发费用同比均实现较大幅度下 降，体现出较强的成本管控能力。同时华大基因表示，将加强信用管控和加大催收力度，目前正在通过 诉讼、以物抵债等多种途径进行应收账款管理，力争应收余额和账期控制在合理水平。 三级预防业务领域的遗传病基因检测 营业收入同比增长 尽管短期业绩承压，但华大基因各业务在产品结构优化与场景落地方面取得显著进展。具体来看，2025 年，华大基因生育健康业务营收有所下降，主要受出生人口减少及集采政策影响，无创产前基因检测样 本量及产品价格同比下滑。不过另一方面，华大基因也在持续加强生育健康业务入院布局，院内销售的 试剂收入列入精准医学综合解决方案板块。为应对无创产前 ...

1月27日晚间，华大基因发布2025年度业绩预告。业绩预告显示，公司2025年营业收入预计为36亿元至 39亿元，归母净利润同比大幅减亏。 华大基因表示，业绩变动主要受行业竞争加剧导致部分产品毛利率下降幅度较大、客户回款周期延长带 来的信用减值损失增加，以及对部分交付中心进行战略调整所计提的资产减值等因素影响。 值得注意的是，华大基因通过精益运营有效控制费用，销售、管理及研发费用同比均实现较大幅度下 降，体现出较强的成本管控能力。同时华大基因表示，将加强信用管控和加大催收力度，目前正在通过 诉讼、以物抵债等多种途径进行应收账款管理，力争应收余额和账期控制在合理水平。 尽管短期业绩承压，但华大基因各业务在产品结构优化与场景落地方面取得显著进展。具体来看，2025 年，华大基因生育健康业务营收有所下降，主要受出生人口减少及集采政策影响，无创产前基因检测样 本量及产品价格同比下滑。不过另一方面，华大基因也在持续加强生育健康业务入院布局，院内销售的 试剂收入列入精准医学综合解决方案板块。为应对无创产前检测基础版产品价格下降的风险，华大基因 推动无创产前检测全因系列等高毛利产品的布局，以优化业务结构。与此同时，公司在三 ...

南财智讯1月27日电，华大基因发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-63,000万元至-53,000万元，即净亏损5.30亿元—6.30亿元；预计2025年全年归属于上市公司股东的扣 除非经常性损益的净利润为-67,500万元至-54,500万元。业绩变动原因说明：（一）预计公司2025年度 营业收入约360,000万元至390,000万元，较上年同期变动幅度为-6.90%～0.86%，预计公司2025年归属于 上市公司股东的净利润约-63,000万元至-53,000万元。业绩变动的主要原因如下：1、受市场需求波动及 行业竞争加剧影响，公司终端服务/产品价格进一步下降，部分产品毛利率较上年同期下降幅度较大。 公司继续主动战略性调整主营业务产品结构，聚焦核心优势产品线经营，推进主营业务稳步发展。公司 生育健康业务营业收入较2024年同期有所下降，主要系市场需求下降、集采政策陆续实施所致，无创产 前基因检测样本量及产品价格同比下滑，公司持续加强生育健康业务入院布局，院内销售的试剂收入列 入在精准医学综合解决方案板块。同时，公司将进一步推动无创产前检测全因系列等高毛利产品的布局 以应对 ...

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. (BGI) demonstrated strong operational resilience and strategic determination in a complex industry environment, with significant improvements in profitability and operational quality despite short-term performance fluctuations [1][2]. Financial Performance - In the first three quarters of 2025, BGI achieved operating revenue of 2.674 billion yuan, with a notable reduction in net profit loss year-on-year. In Q3 alone, the revenue reached 1.042 billion yuan, reflecting a year-on-year growth of 9.19% [1]. Business Growth Areas - BGI's various business segments showed robust growth, particularly in cancer and chronic disease prevention, with colorectal cancer detection revenue increasing by approximately 9%. The infection prevention business saw a revenue increase of about 200% for the PTseq product series, while single-cell sequencing revenue grew by approximately 93%. The comprehensive solutions for precision medicine testing also experienced an 11.2% year-on-year growth [2]. Strategic Focus on Elderly Health - The company is strategically focusing on the health market centered around the elderly population, addressing chronic diseases such as genetic metabolic disorders, cardiovascular diseases, and cognitive impairments. BGI has launched multiple risk assessment products for cognitive disorders and cardiovascular diseases [2]. AI and Data-Driven Innovations - BGI is leveraging big data and artificial intelligence to transition the healthcare industry from expert-driven to data and intelligence-driven models. The company launched the GeneT multimodal model, which is now utilized by 241 partner institutions, enhancing genetic testing capabilities [3]. Health Management Solutions - BGI introduced the 133111i multi-omics health management model, which creates personalized health risk profiles and customizes intervention plans across the health management spectrum. The i99 Smart Health platform further advances health management into a new era of intelligence and personalization [3]. Gene Data Product Development - The company has made strides in gene data value transformation by launching the first domestic gene data products, including the "Hereditary Tumor Variation Knowledge Base" and "Tumor Somatic Variation and Medication Knowledge Base," filling a gap in the domestic market for precision oncology data products [3].

Core Insights - The company reported a decline in revenue and an increase in net loss for the first three quarters of 2025 compared to the previous year [1][2] - The company is facing challenges due to changes in industry demand and intensified market competition [3] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 2.674 billion yuan, a year-on-year decrease of 5.39% [2] - The net loss attributable to shareholders was 21.39 million yuan, an increase of 82.78% year-on-year [1][2] - The net cash flow from operating activities was -436.67 million yuan, a decline of 205.8% year-on-year [1][2] Quarterly Breakdown - In Q3 2025, the company reported operating revenue of 1.042 billion yuan, a year-on-year increase of 9.19% [2] - The net loss attributable to shareholders in Q3 was 27.17 million yuan, an increase of 80.92% year-on-year [1][2] Cost Management - The company has implemented cost control measures, resulting in a decrease in sales expenses by 17.73%, management expenses by 17.76%, and R&D expenses by 16.38% [3] Business Segment Performance - The reproductive health segment generated revenue of 643 million yuan, down 28.4% year-on-year, primarily due to a 36% decline in non-invasive prenatal testing revenue [4] - The oncology and chronic disease prevention segment reported revenue of 358 million yuan, a decrease of 8.8% year-on-year [4] - The infection prevention segment saw revenue growth of 41.7%, reaching 75 million yuan [5] Strategic Developments - The company is focusing on high-margin products in the reproductive health sector to counteract price declines in basic non-invasive prenatal testing [4] - The precision medicine testing solutions segment achieved revenue of 1.124 billion yuan, an increase of 11.2% year-on-year, driven by local clinical application transformations [6] Shareholder Activity - The controlling shareholder, BGI Holdings, has reduced its stake in the company through significant share sales, raising over 1.1 billion yuan in total this year [7][8] - As of the latest report, BGI Holdings and its affiliates hold 31.32% of the company's shares, with a substantial portion pledged as collateral [6][8] Market Performance - As of October 24, the company's stock price was 47.7 yuan per share, with a total market capitalization of 19.954 billion yuan [9]

Core Viewpoint - BGI Genomics reported a strong financial performance in Q3 2025, with significant growth in net profit despite industry challenges [1][2] Financial Performance - Q3 revenue reached 1.042 billion yuan, a year-on-year increase of 9.19%, while net profit attributable to shareholders grew by 80.92% [1] - For the first three quarters, total revenue was 2.674 billion yuan, with net profit increasing by 82.78% and non-recurring net profit up by 52.04% [1] Business Segment Performance - The reproductive health segment saw revenue of 643 million yuan, a decline attributed to the non-invasive prenatal testing business [1] - The oncology and chronic disease prevention segment generated 358 million yuan, slightly down due to reduced client testing demand [2] - The infection control segment achieved 75 million yuan in revenue, a 41.7% increase, driven by advancements in pathogen sequencing and automation [2] Strategic Adjustments - The company is actively adjusting its business strategies to enhance high-margin product growth and improve operational efficiency [2] - Future outlook suggests a commitment to innovation and strategic development across various business segments to navigate industry challenges [2]

Core Viewpoint - BGI Genomics reported a decline in revenue and an increase in net loss for the first three quarters of 2025, indicating challenges in the industry and increased competition [1][3]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 2.674 billion yuan, a year-on-year decrease of 5.39% [2]. - The net loss attributable to shareholders was 21.39 million yuan, an increase of 82.78% compared to the previous year [1][2]. - The operating cash flow net amount was -437 million yuan, a decline of 205.8% year-on-year [1][2]. Quarterly Performance - In Q3 2025, the company reported revenue of 1.042 billion yuan, a year-on-year increase of 9.19% [2]. - The net loss for Q3 was 27.17 million yuan, an increase of 80.92% compared to the same quarter last year [1][2]. Business Segment Analysis - The reproductive health segment generated revenue of 643 million yuan, down 28.4% year-on-year, primarily due to a 36% decline in non-invasive prenatal testing revenue [3]. - The oncology and chronic disease prevention segment reported revenue of 358 million yuan, an 8.8% decrease year-on-year, attributed to reduced client demand for health check services [4]. - The infection prevention segment saw revenue growth of 41.7%, reaching 75 million yuan, driven by advancements in pathogen sequencing technology [5]. - The multi-omics and synthetic biology segment maintained stable revenue at 452 million yuan, with single-cell sequencing revenue increasing by approximately 93% [6]. Strategic Developments - The precision medicine testing solutions segment achieved revenue of 1.124 billion yuan, an 11.2% increase year-on-year, supported by local clinical application advancements and successful overseas market expansion [7]. - The company is focusing on high-margin products in the reproductive health sector to mitigate risks from declining prices in basic non-invasive prenatal testing [3]. Shareholder Activity - BGI Genomics' major shareholder, BGI Holdings, has significantly reduced its stake, with a recent sale of 16.73 million shares for 7.38 billion yuan [8]. - This marks the second major reduction in 2025, with total cash raised exceeding 1.1 billion yuan from share sales [8].

Core Viewpoint - 华大基因 reported a significant increase in profitability despite industry challenges, with a notable rise in net profit and effective cost management [1][2][3] Financial Performance - The company achieved a revenue of 2.674 billion yuan in the first three quarters, with a year-on-year net profit increase of 82.78% and a non-recurring net profit increase of 52.04% [1] - In Q3 alone, revenue reached 1.042 billion yuan, marking a 9.19% year-on-year growth, while net profit surged by 80.92% [1] Business Segment Analysis - **Fertility Health Business**: Revenue declined to 643 million yuan, primarily due to a 36% drop in non-invasive prenatal testing revenue, influenced by structural changes in revenue accounting [1][2] - **Tumor and Chronic Disease Prevention**: Revenue slightly decreased to 358 million yuan, attributed to reduced client demand for testing services, with a notable 9% growth in colorectal cancer detection revenue [2] - **Infection Control Business**: Revenue increased by 41.7% to 75 million yuan, driven by advancements in pathogen sequencing and automation, with PTseq product revenue growing by approximately 200% [2] - **Multi-Omics and Synthetic Business**: Revenue remained stable at 452 million yuan, with single-cell sequencing showing a significant growth of about 93% [3] - **Precision Medicine Testing Solutions**: Revenue grew by 11.2% to 1.124 billion yuan, bolstered by successful overseas project implementations [3] Strategic Adjustments - The company is focusing on high-margin products and expanding into emerging overseas markets, particularly in Latin America, to counteract pricing pressures in core products [2] - Continuous operational efficiency improvements through refined management practices are expected to support sustainable growth [3]

Core Insights - BGI Genomics reported a significant recovery in profitability with a net profit of 5.78 million yuan in the first half of 2025, marking a year-on-year increase of 908.64% [1] - The company achieved total revenue of 1.63 billion yuan in the first half, with 960 million yuan generated in the second quarter alone [1] Revenue Breakdown - Precision medicine testing business generated 696 million yuan in overseas markets, reflecting a year-on-year growth of 4.80%, with notable growth in Southeast Asia and a doubling of revenue in emerging markets like Latin America and South Asia [1] - Reproductive health business revenue reached 426 million yuan, with a 15% increase in revenue from genetic disease testing within the tertiary prevention segment [1] - Multi-omics and synthetic business generated 279 million yuan, with single-cell sequencing revenue growing approximately 110% year-on-year [1] - Cancer and chronic disease prevention business revenue was 180 million yuan, with a renewal and launch of the colorectal cancer project expected in the second half of the year [1] - Infection prevention business revenue was 38 million yuan, with PTseq products based on targeted high-throughput sequencing technology seeing a remarkable growth of 242% [1] Technological Advancements - BGI Genomics launched the SIRO high-throughput sequencing AI and localized one-stop solution, enhancing data processing capabilities and supporting business expansion and research innovation [2] - The company introduced the "i99 Smart Health" multi-omics health management system, utilizing AI technology to provide personalized and precise health management solutions for users [2]

Investment Rating - The investment rating for the company is maintained at "Buy" [1] Core Views - The company has shown a significant improvement in its performance, with a positive net profit in Q2 2025, indicating a recovery trend despite challenges in the first half of the year [1] - The report highlights the potential for further performance improvement driven by cost control and AI-enabled efficiency gains [5] Financial Performance Summary - In the first half of 2025, the company's revenue was CNY 1.631 billion, with a net profit of CNY 6 million, reflecting a year-on-year decline of 13% in revenue and a 68% decline in net profit [1] - Q2 2025 saw revenue of CNY 960 million and a net profit of CNY 58 million, marking a turnaround from negative to positive net profit [1] - The gross margin for the first half of 2025 was 44.65%, down 2.59 percentage points year-on-year, primarily due to a decline in gross margins in some business segments [4] Business Segment Performance - The reproductive health business generated CNY 426 million in revenue, down 29.8% year-on-year, attributed to a decrease in testing volume and pricing [2] - The oncology and chronic disease prevention segment reported revenue of CNY 180 million, down 27.5% year-on-year, with a significant decline in colorectal cancer testing revenue [2] - The multi-omics big data service revenue was CNY 279 million, down 8.3% year-on-year, impacted by geopolitical factors, while single-cell sequencing revenue grew by approximately 110% [3] Future Projections - Revenue projections for 2025-2027 have been adjusted downward by 15% to CNY 3.6 billion, CNY 4.0 billion, and CNY 4.4 billion respectively, with net profit estimates also revised downwards [5] - The report anticipates continued improvement in profitability due to ongoing focus on core business and AI-driven cost reductions [5] Valuation - The target price for the company is set at CNY 57.72, reflecting a price-to-sales ratio of 6.7x for 2025, compared to the industry average of 5.7x [5]